Los ANGELES (Reuters) - Gilead Sciences Inc. said on Thursday that early trial results show Truvada (emtricitabine and tenofovir), its once-daily HIV pill, is better at suppressing the virus that causes AIDS than a twice-daily regimen of Combivir (lamivudine and zidovudine), a drug sold by GlaxoSmithKline Plc.
Preliminary 24-week data from the 411-patient trial were presented in Dublin at the European AIDS Conference.
Gilead said the study showed that 76% of patients who switched to Truvada from Combivir, both in combination with Bristol-Myers Squibb Co.'s Sustiva (efavirenz), achieved very low levels of the virus, compared with 59% before the switch was made.
The most common side effects seen in the trial were nausea, diarrhea and headache, the company said.
Drug makers increasingly are combining HIV drugs into single pills to free HIV patients from the complications of having to take a wide range of medicines at different times of the day.
0 comments:
Post a Comment